share_log

Diversified Trust Co Purchases 4,834 Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII)

Diversified Trust Co Purchases 4,834 Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII)

多元化信託公司購買 4,834 股心血管系統股份有限公司 (NASDAQ: CSII)
Defense World ·  2022/12/26 04:41

Diversified Trust Co grew its position in Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating) by 32.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,634 shares of the medical device company's stock after buying an additional 4,834 shares during the period. Diversified Trust Co's holdings in Cardiovascular Systems were worth $272,000 at the end of the most recent quarter.

多元化信託公司最近向美國證券交易委員會提交的13F文件顯示,該公司第三季度在心血管系統公司的持倉增加了32.7%。該機構投資者持有這家醫療器械公司19,634股票,在此期間又購買了4,834股票。截至最近一個季度末,多元化信託公司在心血管系統公司持有的股份價值27.2萬美元。

Other institutional investors have also modified their holdings of the company. Point72 Hong Kong Ltd bought a new stake in shares of Cardiovascular Systems in the 2nd quarter valued at about $34,000. PNC Financial Services Group Inc. boosted its holdings in shares of Cardiovascular Systems by 32.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,025 shares of the medical device company's stock valued at $68,000 after buying an additional 735 shares in the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of Cardiovascular Systems by 17.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 6,849 shares of the medical device company's stock valued at $98,000 after buying an additional 1,002 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Cardiovascular Systems by 86.3% in the 1st quarter. Captrust Financial Advisors now owns 4,665 shares of the medical device company's stock valued at $105,000 after buying an additional 2,161 shares in the last quarter. Finally, Group One Trading L.P. boosted its holdings in shares of Cardiovascular Systems by 226.5% in the 1st quarter. Group One Trading L.P. now owns 6,200 shares of the medical device company's stock valued at $140,000 after buying an additional 11,100 shares in the last quarter. 86.61% of the stock is currently owned by institutional investors.

其他機構投資者也調整了對該公司的持股。Point72 Hong Kong Ltd在第二季度購買了心血管系統公司的新股,價值約34,000美元。PNC金融服務集團(PNC Financial Services Group Inc.)在第一季度增持了32.1%的心血管系統股票。PNC金融服務集團(PNC Financial Services Group Inc.)現在持有這家醫療設備公司3,025股股票,價值6.8萬美元,該公司在上個季度又購買了735股。美國互惠資本管理有限責任公司在第二季度增持了17.1%的心血管系統股票。美國互惠資本管理有限責任公司現在持有這家醫療設備公司6849股,價值98,000美元,在上個季度又購買了1,002股。CapTrust Financial Advisors在第一季度將其在心血管系統公司的股票持有量增加了86.3%。CapTrust Financial Advisors現在持有這家醫療設備公司4,665股股票,價值10.5萬美元,上個季度又購買了2,161股。最後,Group one Trading L.P.在第一季度增持了226.5%的心血管系統股票。Group One Trading L.P.在上個季度又購買了11,100股後,現在持有這家醫療設備公司6,200股股票,價值14萬美元。86.61%的股票目前由機構投資者持有。

Get
到達
Cardiovascular Systems
心血管系統
alerts:
警報:

Cardiovascular Systems Stock Performance

心血管系統股票表現

Shares of NASDAQ CSII opened at $13.32 on Monday. The company has a current ratio of 6.22, a quick ratio of 5.20 and a debt-to-equity ratio of 0.08. Cardiovascular Systems, Inc. has a 12 month low of $12.26 and a 12 month high of $23.47. The company has a 50 day simple moving average of $14.08 and a two-hundred day simple moving average of $14.40. The stock has a market cap of $557.87 million, a price-to-earnings ratio of -13.32 and a beta of 0.86.

週一,納斯達克中證股價開盤報13.32美元。該公司的流動比率為6.22,速動比率為5.20,債務權益比率為0.08。心血管系統公司的股價為12.26美元的12個月低點和23.47美元的12個月高位。該公司的50日簡單移動均線切入位在14.08美元,200日簡單移動均線切入位在14.40美元。該股市值為5.5787億美元,市盈率為-13.32倍,貝塔係數為0.86。

Cardiovascular Systems (NASDAQ:CSII – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Cardiovascular Systems had a negative net margin of 16.40% and a negative return on equity of 15.51%. The business had revenue of $59.67 million for the quarter, compared to analyst estimates of $59.33 million. As a group, analysts predict that Cardiovascular Systems, Inc. will post -0.67 earnings per share for the current year.
心血管系統公司(納斯達克代碼:CSII-GET Rating)上一次公佈季度收益數據是在11月3日星期四。這家醫療器械公司公佈了該季度每股收益(0.27美元),低於普遍預期的(0.24美元)和(0.03美元)。心血管系統公司的淨利潤率為負16.40%,淨資產回報率為負15.51%。該業務本季度營收為5967萬美元,而分析師預期為5933萬美元。分析師預計,作為一個整體,心血管系統公司本年度的每股收益將為0.67美元。

Analysts Set New Price Targets

分析師設定新的價格目標

A number of research firms have recently weighed in on CSII. Barclays began coverage on shares of Cardiovascular Systems in a report on Wednesday, December 21st. They issued an "equal weight" rating and a $15.00 price target on the stock. StockNews.com began coverage on shares of Cardiovascular Systems in a research note on Wednesday, October 12th. They issued a "hold" rating for the company. Finally, Lake Street Capital began coverage on shares of Cardiovascular Systems in a research note on Wednesday, December 14th. They issued a "buy" rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $20.00.

一些研究公司最近加入了對CSII的看法。巴克萊在12月21日星期三的一份報告中開始報道心血管系統的股票。他們給出了“同等權重”的評級和15.00美元的目標價。StockNews.com在10月12日星期三的一份研究報告中開始報道心血管系統的股票。他們對該公司的評級為“持有”。最後,Lake Street Capital在12月14日星期三的一份研究報告中開始報道心血管系統的股票。他們對該公司的評級為“買入”,目標價為25美元。一名分析師對該股的評級為賣出,兩名分析師對該股的評級為持有,兩名分析師對該公司的評級為買入。根據MarketBeat.com的數據,該股目前的平均評級為持有,平均目標價為20.00美元。

Cardiovascular Systems Company Profile

心血管系統公司簡介

(Get Rating)

(獲取評級)

Cardiovascular Systems, Inc, a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

心血管系統公司是一家醫療技術公司,在美國和國際上開發和銷售治療外周和冠狀動脈疾病的解決方案。該公司提供外周動脈疾病產品,包括基於導管的平臺,用於治療膝蓋以上和膝蓋以下的各種斑塊類型,包括鈣化斑塊,以及解決與手術、導管和藥物治療替代方案相關的各種限制;以及外周支持產品。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Cardiovascular Systems (CSII)
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • Cintas Beats Inflation With Operating Leverage
  • Your Decision to Buy Palantir May Simply Be a Matter of Time
  • 免費獲取StockNews.com心血管系統研究報告(CSII)
  • MarketBeat:回顧一週12/19-12/23
  • 這些鋼鐵製造商理應在2023年觀察名單上佔有一席之地
  • 通脹降温,標普500指數何去何從
  • Cintas以經營槓桿擊敗通脹
  • 你買下Palantir的決定可能只是個時間問題

Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems, Inc. (NASDAQ:CSII – Get Rating).

想看看其他對衝基金持有哪些中證指數嗎?訪問HoldingsChannel.com獲取心血管系統公司(納斯達克代碼:CSII-GET評級)的最新13F申報文件和內幕交易信息。

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

接受《每日心血管系統》新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對心血管系統和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論